Sinopharm Group Co. Ltd. — Earnings Release 2025

Oct 21, 2025

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

国药集团

SINOPHARM

國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 21 October 2025 (the "Announcement") in relation to the preliminary financial data for the nine months ended 30 September 2025 of China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data and indicators of Sinopharm Accord for the nine months ended 30 September 2025 as set out in the Announcement.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."

---

Unit: Ten thousand Yuan
Currency: RMB

PRINCIPAL UNAUDITED FINANCIAL DATA AND INDICATORS OF SINOPHARM ACCORD

	January-September 2025	January-September 2024	Increase/Decrease
Total Revenue	5,512,449.07	5,646,635.45	-2.38%
Operating profit	133,347.76	134,444.49	-0.82%
Total profit	131,765.48	135,646.33	-2.86%
Net profit attributable to shareholders of the listed company	95,711.85	106,554.21	-10.18%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	92,301.90	102,413.89	-9.87%
Basic earnings per share (Yuan)	1.72	1.91	-9.95%
Weighted average return on net assets	5.29%	5.99%	Decreased by 0.70 percentage point
	July-September 2025	July-September 2024	Increase/Decrease
Total Revenue	1,832,789.23	1,868,037.39	-1.89%
Operating profit	40,698.11	39,558.48	2.88%
Total profit	39,954.15	39,849.44	0.26%
Net profit attributable to shareholders of the listed company	29,121.12	32,205.49	-9.58%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	28,015.75	31,276.04	-10.42%
Basic earnings per share (Yuan)	0.52	0.58	-10.34%
Weighted average return on net assets	1.59%	1.80%	Decreased by 0.21 percentage point
	At the end of the Reporting Period	At the beginning of the Reporting Period	Increase/Decrease
Total assets	5,055,886.26	4,755,586.04	6.31%
Equity attributable to shareholders of listed company	1,842,994.62	1,766,952.84	4.30%
Share capital (in 0’000 shares)	55,656.51	55,656.51	0.00%
Net assets per share attributable to shareholders of listed company (Yuan)	33.11	31.75	4.28%

Note: The above data is filled in according to the consolidated financial statements of Sinopharm Accord.

2

---

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

For the period from January to September 2025, Sinopharm Accord achieved a revenue of RMB 55.124 billion, representing a year-on-year decrease of 2.38%; net profit attributable to shareholders of the listed company was RMB 0.957 billion, representing a year-on-year decrease of 10.18%. Correspondingly, basic earnings per share decreased by 9.95% year-on-year, and weighted average return on net assets decreased by 0.70 percentage point year-on-year. In the third quarter of 2025, Sinopharm Accord achieved a revenue of RMB 18.328 billion, representing a year-on-year decrease of 1.89%; net profit attributable to shareholders of the listed company was RMB 0.291 billion, representing a year-on-year decrease of 9.58%. The performance of each segment is as follows:

From January to September 2025, the distribution segment achieved a revenue of RMB 40.594 billion, representing a year-on-year decrease of 0.59%; and net profit of RMB 0.723 billion, representing a year-on-year decrease of 7.32%. In the third quarter, policy and market competition pressures faced by the distribution business persisted. However, Sinopharm Accord achieved a stabilization and recovery in distribution revenue through continuous optimization of its business structure. Meanwhile, due to the longer payment cycles of some downstream customers, provisions for credit impairment losses increased year-on-year, leading to a decline in profit. However, Sinopharm Accord adhered to business adjustments and cost control, resulting in a narrowing profit decline. The retail segment (namely "Sinopharm Holding Guoda Drugstore Co., Ltd.", hereinafter referred to as "Guoda Drugstore") achieved a revenue of RMB 15.226 billion, representing a year-on-year decrease of 7.14%; and net profit of RMB 13 million, representing a year-on-year increase of 133.91%. Affected by the intensifying market environment challenges and ongoing strategic store closure measures, Guoda Drugstore's sales revenue slightly decreased. However, Guoda Drugstore continuously optimized its procurement system, focused on proprietary brands and centralized procurement, thereby enhancing its profitability. Simultaneously, by closing inefficient stores and improving per-store output, it effectively reduced fixed expenditure such as labor and rent. During the Reporting Period, Guoda Drugstore's net profit achieved year-on-year growth.

Facing a complex and ever-changing external environment, Sinopharm Accord will steadfastly focus on the key directions of "increasing revenue, reducing expenditure, and improving efficiency". It will accelerate digital transformation, deepen organizational reform and refined management, adjust its business structure, and continuously enhance its operational quality and risk resilience to achieve stable and healthy development.

Shareholders and public investors should note that the principal unaudited financial data and indicators of Sinopharm Accord during the Reporting Period contained in this announcement are only preliminary accounting data, which have not been audited by an accounting firm, and the final data to be disclosed in the third quarter report of Sinopharm Accord may differ.

By order of the Board

Sinopharm Group Co. Ltd.

Zhao Bingxiang

Chairman

Shanghai, the PRC

21 October 2025

---

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Sun Jinglin; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.

4